Literature DB >> 26385692

Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension.

Shraddha Nayak1,2, Md Abdul H Khan1, Tina C Wan1,2, Hong Pei3, Joel Linden3, Melinda R Dwinell4, Aron M Geurts2,4, John D Imig1, John A Auchampach5,6.   

Abstract

The A(2B) adenosine receptor (AR) has emerged as a unique member of the AR family with contrasting roles during acute and chronic disease states. We utilized zinc-finger nuclease technology to create A(2B)AR gene (Adora2b)-disrupted rats on the Dahl salt-sensitive (SS) genetic background. This strategy yielded a rat strain (SS-Adora2b mutant rats) with a 162-base pair in-frame deletion of Adora2b that included the start codon. Disruption of A(2B)AR function in SS-Adora2b mutant rats was confirmed by loss of agonist (BAY 60-6583 or NECA)-induced cAMP accumulation and loss of interleukin-6 release from isolated fibroblasts. In addition, BAY 60-6583 produced a dose-dependent increase in glucose mobilization that was absent in SS-Adora2b mutants. Upon initial characterization, SS-Adora2b mutant rats were found to exhibit increased body weight, a transient delay in glucose clearance, and reduced proinflammatory cytokine production following challenge with lipopolysaccharide (LPS). In addition, blood pressure was elevated to a greater extent (∼15-20 mmHg) in SS-Adora2b mutants as they aged from 7 to 21 weeks. In contrast, hypertension augmented by Ang II infusion was attenuated in SS-Adora2b mutant rats. Despite differences in blood pressure, indices of renal and cardiac injury were similar in SS-Adora2b mutants during Ang II-augmented hypertension. We have successfully created and validated a new animal model that will be valuable for investigating the biology of the A(2B)AR. Our data indicate varying roles for A(2B)AR signaling in regulating blood pressure in SS rats, playing both anti- and prohypertensive roles depending on the pathogenic mechanisms that contribute to blood pressure elevation.

Entities:  

Keywords:  Adenosine; Adenosine receptor; Angiotensin; Gene targeting; Hypertension; Metabolic disease

Mesh:

Substances:

Year:  2015        PMID: 26385692      PMCID: PMC4648794          DOI: 10.1007/s11302-015-9470-7

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  40 in total

1.  Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor.

Authors:  Laura M Kreckler; Tina C Wan; Zhi-Dong Ge; John A Auchampach
Journal:  J Pharmacol Exp Ther       Date:  2005-12-09       Impact factor: 4.030

Review 2.  A(2B) adenosine receptors in immunity and inflammation.

Authors:  György Haskó; Balázs Csóka; Zoltán H Németh; E Sylvester Vizi; Pál Pacher
Journal:  Trends Immunol       Date:  2009-05-07       Impact factor: 16.687

Review 3.  The resurgence of A2B adenosine receptor signaling.

Authors:  Carol M Aherne; Emily M Kewley; Holger K Eltzschig
Journal:  Biochim Biophys Acta       Date:  2010-05-28

4.  Afferent arteriolar vasodilator effect of adenosine predominantly involves adenosine A2B receptor activation.

Authors:  Ming-Guo Feng; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2010-05-12

5.  Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury.

Authors:  Chun-Xiao Sun; Hongyan Zhong; Amir Mohsenin; Eva Morschl; Janci L Chunn; Jose G Molina; Luiz Belardinelli; Dewan Zeng; Michael R Blackburn
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

6.  HIF-dependent induction of adenosine A2B receptor in hypoxia.

Authors:  Tianqing Kong; Karen A Westerman; Marion Faigle; Holger K Eltzschig; Sean P Colgan
Journal:  FASEB J       Date:  2006-11       Impact factor: 5.191

7.  Generation of gene-specific mutated rats using zinc-finger nucleases.

Authors:  Aron M Geurts; Gregory J Cost; Séverine Rémy; Xiaoxia Cui; Laurent Tesson; Claire Usal; Séverine Ménoret; Howard J Jacob; Ignacio Anegon; Roland Buelow
Journal:  Methods Mol Biol       Date:  2010

8.  Development and characteristics of inbred strains of Dahl salt-sensitive and salt-resistant rats.

Authors:  J P Rapp; H Dene
Journal:  Hypertension       Date:  1985 May-Jun       Impact factor: 10.190

Review 9.  Nucleotide signalling during inflammation.

Authors:  Marco Idzko; Davide Ferrari; Holger K Eltzschig
Journal:  Nature       Date:  2014-05-15       Impact factor: 49.962

10.  The A2b adenosine receptor modulates glucose homeostasis and obesity.

Authors:  Hillary Johnston-Cox; Milka Koupenova; Dan Yang; Barbara Corkey; Noyan Gokce; Melissa G Farb; Nathan LeBrasseur; Katya Ravid
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

View more
  5 in total

1.  Lung injury pathways: Adenosine receptor 2B signaling limits development of ischemic bronchiolitis obliterans organizing pneumonia.

Authors:  John C Densmore; Terry R Schaid; Paul M Jeziorczak; Meetha Medhora; Said Audi; Shraddha Nayak; John Auchampach; Melinda R Dwinell; Aron M Geurts; Elizabeth R Jacobs
Journal:  Exp Lung Res       Date:  2017-03-07       Impact factor: 2.459

2.  Adenosine Receptors Influence Hypertension in Dahl Salt-Sensitive Rats: Dependence on Receptor Subtype, Salt Diet, and Sex.

Authors:  Edwin K Jackson; Delbert G Gillespie; Zaichuan Mi; Dongmei Cheng
Journal:  Hypertension       Date:  2018-06-25       Impact factor: 10.190

3.  Novel Anti-Melanogenesis Properties of Polydeoxyribonucleotide, a Popular Wound Healing Booster.

Authors:  Tai Kyung Noh; Bo Young Chung; Su Yeon Kim; Mi Hye Lee; Moon Jung Kim; Choon Shik Youn; Mi Woo Lee; Sung Eun Chang
Journal:  Int J Mol Sci       Date:  2016-09-01       Impact factor: 5.923

4.  Adenosine Receptor-Mediated Cardioprotection-Current Limitations and Future Directions.

Authors:  Robert D Lasley
Journal:  Front Pharmacol       Date:  2018-04-04       Impact factor: 5.810

Review 5.  Genetic Modifications to Alter Blood Pressure Level.

Authors:  Hiroki Ohara; Toru Nabika
Journal:  Biomedicines       Date:  2022-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.